695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)
已完结10由 wuhu 发布于 2025/10/21 21:48:22
DOI:10.1136/jitc-2023-sitc2023.0695
作者:Parneet Cheema, Sylvia Hartl, Marianna Koczywas, Maximilian Hochmair, Frances A Shepherd, Quincy Chu, Giuseppe Galletti, Mark Gustavson, Sonia Iyer, J Carl Barrett, Brent Evans, Rakesh Kumar, Jan Cosa
文献类型:期刊论文
补充材料:只需要正文